3D Printed Drugs Market

Future Market Insights suggests that within the 3D printed drugs landscape, the construction of dedicated commercial-scale 3D pharmaceutical production facilities is moving additive drug manufacturing from proof-of-concept into validated industrial production. FMI analysts identify FDA IND clearances for 3D printed drug candidates with complex release geometries as the central pivot point, effectively establishing regulatory precedent for additive pharmaceutical manufacturing beyond the original Spritam approval.